Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation on ihosairaus, jolle on tunnusomaista lisääntynyt pigmentti ihossa ihotulehduksen seurauksena. Postinflammatory hyperpigmentation voi johtua pitkäaikaisesta auringosta, tulehduksesta tai muista ihovaurioista, mukaan lukien akneen liittyvät vauriot. Ihmiset, joilla on tummemmat ihonsävyt, ovat yleensä alttiimpia hyperpigmentaatiolle liiallisessa auringonpaisteessa.
☆ Saksan vuoden 2022 Stiftung Warentest -tuloksissa kuluttajien tyytyväisyys ModelDermiin oli vain hieman alhaisempi kuin maksullisiin telelääketieteen konsultaatioihin.
References
Postinflammatory hyperpigmentation (PIH) on yleinen iho-ongelma, joka tapahtuu ihotulehduksen tai -vamman jälkeen. Se kestää pitkään ja on pahempi ihmisillä, joilla on tummempi iho (Fitzpatrick skin types III–VI) . Vaikka se usein paranee itsestään, tämä voi kestää hetken, joten hoitoa tarvitaan usein pitkään. Erilaisten hoitojen yhdistäminen toimii parhaiten.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation on yleinen ihotulehduksen jälki. Sillä on taipumus vaikuttaa tummaihoisiin henkilöihin vakavammin ja useammin. Tutkimukset osoittavat, että ongelmat, kuten postinflammatory hyperpigmentation , ovat yksi tärkeimmistä syistä, miksi ihmiset, joilla on tummempi iho, hakeutuvat dermatologiseen hoitoon. Varhainen hoito on ratkaisevan tärkeää postinflammatory hyperpigmentation :n ratkaisemiseksi, ja se alkaa yleensä alkuperäisen tulehdustilan hallinnasta. Ensimmäisessä hoitolinjassa käytetään tyypillisesti ihoa vaalentäviä paikallisia aineita sekä aurinkovoidetta suojaamaan. Nämä aineet, kuten hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , voivat tehokkaasti vähentää liiallista pigmentaatiota. Lisäksi retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy käytetään myös depigmentointiaineina, ja uusia hoitoja on tulossa. Vaikka paikalliset hoidot ovat yleensä tehokkaita pintatason hyperpigmentaatiossa, toimenpiteet (laser, chemical peel) voivat olla tarpeen itsepäisille tapauksille. On tärkeää olla varovainen näiden hoitojen kanssa, jotta vältetään ärsytys ja postinflammatory hyperpigmentation :n paheneminen.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
